Europe Non-steroidal Anti-inflammatory Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration (Oral, Topical and Others), By Distribution Channel, By Route of Disease Indication, By Country and Growth Forecast, 2022 - 2028

Europe Non-steroidal Anti-inflammatory Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration (Oral, Topical and Others), By Distribution Channel, By Route of Disease Indication, By Country and Growth Forecast, 2022 - 2028

The Europe Non-steroidal Anti-inflammatory Drugs Market would witness market growth of 5.3% CAGR during the forecast period (2022-2028).

As NSAID research, production, and marketing operations include a large number of market participants, they frequently develop organic and inorganic growth strategies to increase their market share.

The availability of a wide range of NSAID preparations is also anticipated to support growth. For example, Pfizer Inc.'s Ketorolac tromethamine is used to treat fairly intense acute pain that necessitates opioid analgesia. Additionally, the GSK Group of Companies' top company for relieving headaches is Excedrin, which combines caffeine, aspirin, and paracetamol. Over the projected period, it is expected that a strong market coverage of important brands and an increase in the launch of combination medications will fuel growth.

By the 2011 Five European Countries (5EU) National Health and Wellness Survey (NHWS), that comprised 57 512 respondents from Germany, France, Spain, Italy, and the UK, individuals with self-reported peripheral joint OA were chosen. 19% of adult Europeans experience chronic pain that ranges from mild to severe intensity, which has a significant impact on their social and professional lives. Probably half got subpar pain care, and only few were treated by pain experts. Even though there were disparities among the 16 nations, researchers have established that chronic pain is a significant issue in European healthcare that requires greater attention.

The Germany market dominated the Europe Non-steroidal Anti-inflammatory Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,663 Million by 2028. The UK market is anticipated to grow at a CAGR of 4.4% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 6% during (2022 - 2028).

Based on Route of Administration, the market is segmented into Oral, Topical and Others. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Route of Disease Indication, the market is segmented into Arthritis, Migraine, Ophthalmic Diseases and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., GlaxoSmithKline PLC, Bayer AG, Teva Pharmaceuticals Industries Ltd., Eli Lilly And Company, Sanofi S.A., AstraZeneca PLC, Viatris, Inc., and Merck & Co., Inc.

Scope of the Study

Market Segments covered in the Report:

By Route of Administration

  • Oral
  • Topical
  • Others
By Distribution Channel
  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy
By Disease Indication
  • Arthritis
  • Migraine
  • Ophthalmic Diseases
  • Others
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • Dr. Reddy’s Laboratories Ltd.
  • Pfizer, Inc.
  • GlaxoSmithKline PLC
  • Bayer AG
  • Teva Pharmaceuticals Industries Ltd.
  • Eli Lilly And Company
  • Sanofi S.A.
  • AstraZeneca PLC
  • Viatris, Inc.
  • Merck & Co., Inc.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Non-steroidal Anti-inflammatory Drugs Market, by Route of Administration
1.4.2 Europe Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel
1.4.3 Europe Non-steroidal Anti-inflammatory Drugs Market, by Disease Indication
1.4.4 Europe Non-steroidal Anti-inflammatory Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent Strategies deployed in Non-steroidal Anti-inflammatory Drugs Market
Chapter 4. Europe Non-steroidal Anti-inflammatory Drugs Market by Route of Administration
4.1 Europe Oral Market by Country
4.2 Europe Topical Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel
5.1 Europe Retail Pharmacy Market by Country
5.2 Europe Hospital Pharmacy Market by Country
5.3 Europe Online Pharmacy Market by Country
Chapter 6. Europe Non-steroidal Anti-inflammatory Drugs Market by Disease Indication
6.1 Europe Arthritis Market by Country
6.2 Europe Migraine Market by Country
6.3 Europe Ophthalmic Diseases Market by Country
6.4 Europe Others Market by Country
Chapter 7. Europe Non-steroidal Anti-inflammatory Drugs Market by Country
7.1 Germany Non-steroidal Anti-inflammatory Drugs Market
7.1.1 Germany Non-steroidal Anti-inflammatory Drugs Market by Route of Administration
7.1.2 Germany Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel
7.1.3 Germany Non-steroidal Anti-inflammatory Drugs Market by Disease Indication
7.2 UK Non-steroidal Anti-inflammatory Drugs Market
7.2.1 UK Non-steroidal Anti-inflammatory Drugs Market by Route of Administration
7.2.2 UK Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel
7.2.3 UK Non-steroidal Anti-inflammatory Drugs Market by Disease Indication
7.3 France Non-steroidal Anti-inflammatory Drugs Market
7.3.1 France Non-steroidal Anti-inflammatory Drugs Market by Route of Administration
7.3.2 France Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel
7.3.3 France Non-steroidal Anti-inflammatory Drugs Market by Disease Indication
7.4 Russia Non-steroidal Anti-inflammatory Drugs Market
7.4.1 Russia Non-steroidal Anti-inflammatory Drugs Market by Route of Administration
7.4.2 Russia Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel
7.4.3 Russia Non-steroidal Anti-inflammatory Drugs Market by Disease Indication
7.5 Spain Non-steroidal Anti-inflammatory Drugs Market
7.5.1 Spain Non-steroidal Anti-inflammatory Drugs Market by Route of Administration
7.5.2 Spain Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel
7.5.3 Spain Non-steroidal Anti-inflammatory Drugs Market by Disease Indication
7.6 Italy Non-steroidal Anti-inflammatory Drugs Market
7.6.1 Italy Non-steroidal Anti-inflammatory Drugs Market by Route of Administration
7.6.2 Italy Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel
7.6.3 Italy Non-steroidal Anti-inflammatory Drugs Market by Disease Indication
7.7 Rest of Europe Non-steroidal Anti-inflammatory Drugs Market
7.7.1 Rest of Europe Non-steroidal Anti-inflammatory Drugs Market by Route of Administration
7.7.2 Rest of Europe Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel
7.7.3 Rest of Europe Non-steroidal Anti-inflammatory Drugs Market by Disease Indication
Chapter 8. Company Profiles
8.1 Dr. Reddy’s Laboratories Ltd.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Product Launches and Product Expansions:
8.2 Pfizer, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Approvals and Trails:
8.3 GlaxoSmithKline PLC
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Approvals and Trails:
8.4 Bayer AG
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trails:
8.5 Teva Pharmaceutical Industries Ltd.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Product Launches and Product Expansions:
8.6 Eli Lilly And Company
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Approvals and Trails:
8.7 Sanofi S.A.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.8 AstraZeneca PLC
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expenses
8.9 Viatris, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Merck & Co., Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expenses

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings